

Sunesis to Present at the 2014 Wedbush Life Sciences Management Access Conference

August 6, 2014 7:00 AM ET

SOUTH SAN FRANCISCO, Calif., Aug. 6, 2014 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that Daniel Swisher, Chief Executive Officer of Sunesis, will be presenting at the 2014 Wedbush Life Sciences Management Access Conference on Tuesday, August 12, 2014 at 9:10 AM Eastern Time at Le Parker Meridien in New York City.

A live webcast of the presentation will be available on the Sunesis website at <http://ir.sunesis.com>. A replay of the webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, QINPREZO[®] (vosaroxin), in multiple indications to improve the lives of people with cancer.

For additional information on Sunesis, please visit <http://www.sunesis.com>.

SUNESIS, QINPREZO and the related logos are trademarks of Sunesis Pharmaceuticals, Inc.

CONTACT: Investor and Media Inquiries:

David Pitts
Argot Partners
212-600-1902

Eric Bjerkholt
Sunesis Pharmaceuticals Inc.
650-266-3717



Sunesis Pharmaceuticals, Inc.